- Biosyntia is a market innovator manufacturing sustainable and natural ingredients using precision fermentation
- The biotech firm has a strong pipeline of active ingredients for use in beauty and nutrition products such as vitamins and antioxidants
- ECBF lead Series B with participation from existing investors, Sofinnova Partners and Novo Seeds
Biosyntia has secured a Series B funding round of 11.5 million euros from a strong syndicate of experienced venture capital investors. The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds, the early-stage investment and company creation team of Novo Holdings A/S. The investment will allow the company to enter the production phase of its first-of-its-kind, natural and sustainable active ingredients as well as expand the pipeline of products. The first product to be commercialized is a bio-based biotin (vitaminB7), for use in dietary supplements, food, and beauty products.
Biosyntia is an industrial biotech company delivering nature’s ingredients at scale both affordably and sustainably. Using cutting-edge biotechnology and proprietary R&D tools and insights, the company is developing first-of-its-kind precision fermentation processes to replace fossil-based alternatives. Its vision is to develop a natural and environmentally-friendly production process of essential nutritional active ingredients, reducing the use of petrochemically-based processes and driving a positive environmental impact. The company today has several commercial partnerships, including collaborations with large market players such as Givaudan and WACKER.
“Our team is truly proud of the recognition this investment gives. The investment enables us to finally offer customers the first and only natural and sustainable alternative to what is available for them today”, says Martin Plambech, CEO of Biosyntia, and continues “with ECBF joining Sofinnova Partners and Novo Seeds as investors, we improve an already strong investor base. Combined with our promising pipeline of ingredients, we are in the making of a new, global fermentation-based ingredient producer that can challenge today’s incumbents.”
“We are very excited to strengthen ECBF’s industrial biotech portfolio by joining with Biosyntia and its current investors in the story of a sustainable change that has a very strong commercial basis. Vitamins and other ingredients should be produced from bio-based instead of fossil-based sources, which unfortunately is usually not the case today. Biosyntia has a promising position to change that, starting with their B-vitamins programs, where the company already is a technology leader”, states Jowita Sewerska, Investment Director with ECBF.
For further information, please contact:
Martin Plambech, CEO, Biosyntia, firstname.lastname@example.org
Biosyntia is an industrial biotech company developing bio-based manufacturing processes with all critical capabilities for success in-house – stretching from microbial engineering, fermentation optimization, product purification, formulation to sales. The company is today 20 scientists and business developers, which operates from Biosyntia’s lab and offices in Copenhagen, Denmark. Biosyntia focuses especially at developing more natural and sustainable processes for active ingredients used in beauty and nutrition such as vitamins, antioxidants, and similar ingredients. The company has developed proprietary technologies such as Biosynthetic Selections™, which dramatically reduce the risk, cost and time for developing fermentation processes. The company has won more than 15 recognition awards, including being one of the most innovative SMEs in Europe.
For more information, please visit: of www.biosyntia.com
About European Circular Bioeconomy Fund
The European Circular Bioeconomy Fund (ECBF) invests growth capital in ambitious and visionary entrepreneurs and encourages private and public investors to assist in the development of late-stage bioeconomy companies. The fund aims to make sustainable investments in our future and speed up the shift from a fossil-based to a circular, bio-based economy. Headquartered in Bonn and with a total fund volume of € 300m, to which the European Investment Bank (EIB)has committed €100 million, ECBF will be an important financial instrument in achieving the European Green Deal goals of making Europe climate-neutral by2050.
For more information, please visit: www.ecbf.vc About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5billion under management.
For more information, please visit: sofinnovapartners.com
About Novo Holdings A/S
Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets.
Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Novo Seeds is the early-stage investment and company creation team of Novo Holdings, focusing on identifying, building and investing in exceptional startups founded on strong science. For more information, please visit: www.novoholdings.dk
Only plant-based raw materials will be used in the production of fermentation-based biotin (photo: BIOSYNTIA).